NL-OMON22654已完成不适用

Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Refractory Crohn's Disease

eids Universitair Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年2月28日

研究概览

简要总结

Duijvestein M, van den Brink GR, Hommes DW. Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. Journal of Crohn's and Colitis (2008) 2, 99¡V106

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Men and women > 18 years of age.
•2. Subject is willing to participate in the study and has signed the informed consent.

排除标准

•1. Patients with evidence of infection or abscesses.
•2. Patients suffering from renal- or hepatic failure.

研究者

发起方

eids Universitair Medisch Centrum

相似试验

已完成

不适用

Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Refractory Crohn*s Diseasemorbus Crohn10017969Crohn's Disease

NL-OMON31150eids Universitair Medisch Centrum10

已完成

不适用

Bone marrow derived mesenchymal stem cells for the treatment of allograft rejection after renal transplantatioaandoeningen na niertransplantatieallograft rejectionrejection after (renal) transplantation10038430

NL-OMON31649eids Universitair Medisch Centrum15

已完成

1 期

Mesenchymal Stem Cells and Subclinical RejectionOrgan Transplantation

NCT00734396Leiden University Medical Center15

进行中（未招募）

不适用

Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.

EUCTR2012-002553-38-ESItziar Astigarraga Aguirre

已完成

1 期

Perinatal Arterial Stroke Treated With Stromal Cells IntranasallyPerinatal Arterial Ischemic StrokeNeonatal Stroke

NCT03356821UMC Utrecht10